OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Schoenfeld on Low-Dose Radiation Plus Immunotherapy in Head and Neck Cancer

February 2nd 2017

Jonathan D. Schoenfeld, MD, MPhil, MPH, director, melanoma radiation oncology, physician, assistant professor of radiation oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses potential combination regimens of low-dose radiation therapy and immunotherapy to treat patients with head and neck cancer.

Dr. Neelapu on Next Steps With KTE-C19 in Lymphoma

February 2nd 2017

Sattva S. Neelapu, MD, associate professor, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the next steps with KTE-C19, an anti-CD19 chimeric antigen receptor T-cell therapy explored in the ZUMA-1 trial for patients with aggressive lymphomas.

Dr. Giralt on Future of Transplant in Multiple Myeloma

February 2nd 2017

Sergio Giralt, MD, a professor of Medicine at Memorial Sloan Kettering Cancer Center, discusses the future role of transplantation in patients with multiple myeloma as well as other hematologic malignancies.

Dr. Muggia on the GOG 252 Trial in Ovarian Cancer

February 2nd 2017

Franco M. Muggia, MD, PhD, professor, Department of Medicine, NYU Langone Medical Center, discusses the GOG 252 trial, which looked at the use of intravenous versus intraperitoneal chemotherapy in the treatment of patients with ovarian cancer.

Dr. Brufsky on the COLET Trial for Triple-Negative Breast Cancer

February 2nd 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses the COLET trial combining cobimetinib (Cotellic) and paclitaxel (Abraxane) as a treatment for patients with triple-negative breast cancer (TNBC).

Dr. Gong on Adverse Events of TKI VEGF-Directed Therapy in RCC

February 2nd 2017

Jun Gong, MD, fellow, City of Hope, discusses adverse events (AEs) associated with TKI/VEGF-directed therapy for patients with metastatic renal cell carcinoma (RCC).

Dr. Abida on Future of Hormonal Therapy in Prostate Cancer

February 2nd 2017

Wassim Abida, MD, PhD, Memorial Sloan Kettering Cancer Center, discusses the future of hormonal therapy in prostate cancer.

Dr. Concepcion on Transition to Value-Based Model in Urology

February 1st 2017

Raoul Concepcion, MD, director of the Comprehensive Prostate Center, discusses the impending transition to a value-based model in urology.

Dr. Weiss on Disease-Control Rate of Immunotherapy for Lung Cancer

February 1st 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy as treatment to control disease for patients with lung cancer.

Dr. Goy on the Role of Immunotherapy in Mantle Cell Lymphoma

February 1st 2017

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses immunotherapy agents currently being evaluated in the treatment of patients with mantle cell lymphoma.

Dr. Royce on Progress Being Made in HER2+ Positive Breast Cancer

February 1st 2017

Melanie E. Royce, MD, PhD, co-director, Protocol Review and Monitoring System, member, Women’s Cancers Research Program, associate professor of Medicine, University of New Mexico Comprehensive Cancer Center, discusses some of the progress currently being made in the field of HER2-positive breast cancer.

Dr. Lin on Chemoradiation in Elderly Patients with Esophageal Cancer

February 1st 2017

Steven H. Lin, MD, PhD, associate professor at The University of Texas MD Anderson Center, discusses study of chemoradiation in elderly patients with esophageal cancer.

Dr. Pegram on Margetuximab Plus Chemo in HER2+ Breast Cancer

February 1st 2017

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses the ongoing phase II SOPHIA trial, which is comparing the combination of margetuximab plus chemotherapy with trastuzumab (Herceptin) in patients with HER2-positive breast cancer.

Dr. Finn on Results of RESOURCE Study in Liver Cancer

January 31st 2017

Richard Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses results of the RESOURCE study in advanced liver cancer.

Dr. Klopp on Data Comparing Standard Radiation With IMRT in Gynecologic Malignancies

January 31st 2017

Ann H. Klopp, MD, PhD, an associate professor of Radiation Oncology at The University of Texas MD Anderson Cancer Center, discusses data from a trial comparing standard radiation therapy with intensity-modulated radiation therapy in patients with gynecologic malignancies.

Dr. Finn on Studies of Pembrolizumab for Hepatocellular Carcinoma

January 31st 2017

Richard Finn, MD, associate professor of Medicine at the UCLA David Geffen School of Medicine, discusses studies of pembrolizumab (Keytruda) in patients with previously untreated hepatocellular carcinoma (HCC).

Dr. Petrylak on Ongoing Investigations of Checkpoint Inhibition in Bladder Cancer

January 31st 2017

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses immune checkpoint inhibitors that are currently being evaluated for the treatment of patients with bladder cancer.

Dr. Al-Batran on Paclitaxel Plus Everolimus in Gastric Cancer

January 30th 2017

Salah-Eddin Al-Batran, MD, medical oncologist and director at the Institute of Clinical Cancer Research — Frankfurt, Germany, discusses the results of trial combining everolimus (Afinitor) with paclitaxel in the treatment of patients with gastric cancer.

Dr. Weiss on PD-L1 Biomarker in Lung Cancer

January 30th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses the development of biomarkers in the study of lung cancer.

Dr. Marshall on Molecular Variances Between Right- Versus Left-Sided Colon Cancer

January 30th 2017

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, associate director, Clinical Research, Lombardi Comprehensive Cancer Center at Georgetown University Hospital, discusses molecular variances between right- and left-sided colon cancer.